The recent discovery of the critical involvement of galectins in cancer progression, and in inflammatory and immune responses, has raised this family of β-D-galactoside-binding proteins to the rank of high-priority drug targets by the scientific community. This report will highlight the relevance of glycochemistry toward the efficient development of synthetic galectins inhibitors with high affinity and selectivity, as small molecules or multivalent glycoconjugates.
A. Introduction
Lectins are carbohydrate-binding proteins that are grouped into several families (1, 2) . Among them, galectins (15 mammalian members identified to date) share a consensus amino acid sequence and are recognized for their ability to bind β-galactoside residues (3, 4) . Natural ligands of galectins are N-acetyl lactosamine, lactose and any glycoconjugates with a non-reducing galactoside terminus. The most striking features of galectins are their ability to regulate numerous biological processes (5) , including an active involvement in a number of cellular events including neoplastic transformation, tumor cell survival processes, angiogenesis and tumor metastasis (6, 7) . They are also known to regulate important cell phenomena that are critical for immune cell homeostasis (8) (9) (10) . Their functions are directly related to the ability of galectins to cross-link glycoconjugates harboring multiple galactopyranoside residues (11) . This phenomenon can be explained by the fact that galectins can assemble in three different and specific architectures, i.e., proto-type, tandem repeat-type, and chimera-type (12) . This diversity opens the door for the exploration of a myriad of structural combinations in the quest for the synthesis of potent and optimized inhibitors. Consequently, the scientific community recently directed efforts toward synthetic compounds having high affinities with galectins with the aim of deciphering their biological roles.
Synthetic strategies to prepare galectin inhibitors have already been nicely summarized in reviews by the groups of Nilsson (13, 14) , Mayo (15) , Pieters (16) , and Kiss (17) .To complement these reports, we wish to shed some light on the synthetic pathways specifically leading to sugar-based inhibitors, emphasizing a comprehensive analysis of their chemical structures that is required to properly identify potential clinical candidates. In that purpose and in the interest of clarity, different structural families including monosaccharides, disaccharides, glycoclusters and glycodendrimers will be described separately. It is noteworthy that combinatorial peptide (18) or glycopeptide (19) libraries will not be covered in this review.
B. Structural Features of Galectins
Galectins contain conserved carbohydrate recognition domain (CRD) of about 135 amino acids (20) . For human galectin-3, eight amino acids (Arg144, His158, Asn160, Arg162, Arg186, Asn174, Trp181, and Glu184) interact with the carbohydrate. Considering the fact that the glycan binding site is described by five subsites A-E (21, 22) , the galactose residue of lactose binds in subsite C, while subsite D accommodates the glucose moiety. (Article for special issue on Galectins) SE22 intermediary of a water molecule (not shown);
iv) The 6′-OH directly hydrogen bonds with Arg174 and Glu184; v) A tryptophan residue is located underneath subsite C, allowing hydrophobic interactions with CH-3, CH-4 and CH-5 (proximity of the π orbitals of the aromatic residue) (24); vi) 2-OH directly hydrogen bonds with Arg186; vii) 3-OH group directly hydrogen bonds with Arg162 and Arg186; viii) 6-OH group indirectly hydrogen bonds with Glu184 via a water molecule.
C. Synthetic Inhibitors of Galectins
Galectin inhibitors could be used as anti-inflammatory agents, as immunomodulators or in cancer therapy. For instance, knockout mice lacking galectin-1 or -3 suggest that inhibitors of these proteins could have therapeutic potential in inflammation or asthma intervention (25, 26) . Intense investigations have also been devoted to cancer therapy with galectin-3 as the most studied lectin in this research field. This is exemplified with TD139 (a ditriazolylthiodigalactoside, see section C-2-3), a lead compound resulting from two decades of research; this compound recently passed a Ib/ IIa phase clinical trial in idiopathic pulmonary fibrosis patients (27, 28). Considering the major role of glycochemistry in this particular field, the main purpose of the present section will be centered on the description of the synthesis of some of the most relevant galectin inhibitors developed to date, with a logical classification of synthetic modifications in connection with targeted subsites. The general strategy was based on the use of 1,5-difluoro-2,4-dinitrobenzene that was successively substituted by various amine or thiol nucleophiles (Scheme 1). The sequence was thus initiated with the introduction of one galactoside residue 1 on difluorodinitrobenzene via a controlled nucleophilic aromatic substitution to provide thiogalactoside 2 in 77% yield. Subsequent functionalization was achieved with phenylmethanethiol providing intermediate 3, which was finally transformed into dibenzamide 4 using tin(II) chloride, followed by de-O-acetylation using butylamine.
C-1. Monosaccharides as Synthetic Galectin Inhibitors
The 28-member library was evaluated against galectins-1, -3, -8N and -9N. Using a competitive fluorescence-polarisation assay, the best inhibitor was compound 4 with a K d value of 0.18 mM against galectin-7 and 2.2 mM against galectin-8N (30-32). Also, compound 4 proved to be active against galectin-3 (K d =1.8 mM) and galectin-8N (K d =0.14 mM).
The same year, a 50-member library of anomeric oxime ether derivatives was synthesized as a LacNAc-mimetic (33) The group of Roy used a phase-transfer catalyzed nucleophilic displacement reaction to synthesize aryl O-and S-galactosides in a straightforward way (35) . Under these conditions, the best monosaccharide inhibitor was obtained by the formation of the desired thioether linkage from 7 and 4-methoxythiophenol. Full deprotection of derivative 8 led to candidate 9, which showed inhibitory properties of 2.5 mM against galectin-3 using a hemagglutination assay (Scheme 3). Interestingly, selectivity was achieved as this compound was inactive against galectin-1.
Galactoside-bearing triazoles and isoxazoles were also prepared by the group of Roy (36) . Triazole 11 and isoxazole 13 were prepared using regioselective [1, 3] 
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(IC 50 =5 mM) while compound 13 selectively inhibited galectin-1 (IC 50 =1.25 mM) as measured with a hemagglutination assay.
Targeting hydrolytically stable analogs, the group of Roy used C-allyl galactoside 14 as a precursor for chemical diversifications in a "drug-like" strategy (Scheme 5) (37). First, a Grubbs' cross-metathesis reaction using methyl acrylate afforded compound 15 (38) .
Then, a Heck palladium-catalyzed coupling reaction was efficiently performed using phenyl iodide, yielding the corresponding methyl cinnamate derivative under phase-transfer catalyzed conditions. Deprotection upon treatment with base afforded inhibitor 16, which was active against galectin-1 (IC 50 =0.313 mM), but inactive toward galectin-3 as evaluated using a hemagglutination inhibition assay.
An additional library of fifteen stable glycosides harbouring a β-C-aminothiazole scaffold (37) was also described (Scheme 6).
Galactose derivative 17, under Knoevenagel conditions, afforded β-C-glycosidic ketone 18 in 90% yield over two steps. galactoside derivatives were synthesized using the same synthetic strategy and described a few years later (40) . Interestingly, the derivative having a 1-naphthyl moiety on the 1,2,3-triazole core was determined as the best candidate with a K d of 120 µM against galectin-3 using the same biological assay. The last example of modification of O3/C3 on a galactoside core has been recently described by Nilsson and coworkers (42) .
The authors used a three-component reaction between galactosyl alkyne 30, various tosyl azides, and amines, to give N-sulfonyl amidine galactose derivatives (Scheme 9). This work resulted from a previous study based on the preparation and evaluation of coumaryl and iminocoumaryl derivatized glycosides (43) . As an example of the method used, propargyl galactoside 30 was treated with phenylsulfonyl azide and cyclohexylamine in the presence of CuI to give the corresponding N-phenylsulfonylamidine 31 in an excellent Glycosylation between acceptor 57 and donor 22 was further accomplished using N-iodosuccinimide/TfOH in 75% yield. The N-TCP protecting group was easily converted into the corresponding N-acetate 59 in 83% and a stearic ester was installed on HO-3 in 80% yield. The latter was tagged with a hydrophobic chain (60) to allow rapid purification using reversed solid-phase extraction. were evaluated by using a fluorescence-polarisation assay and revealed a potent affinity for galectin-3 with a K d value of 2.2 µM.
Another example of disaccharide targeting other subsites has been accomplished by the group of Pieters (64) . Novel lactosamine derivatives possessing a 4-(4-phenoxybenzyl) ether linked at their C-3′ position were prepared. Thus, protected glucosamine 95 was glycosylated with 3-bromopropanol using BF 3 ·OEt 2 followed by bromide displacement with sodium azide (Scheme 27). Acceptor 97 was generated after deprotection and selective installation of the O-6 acetate. On the other hand, thiomethylgalactoside donor 100 was easily generated using a three-step protocol. Galactoside 98 was treated with dibutyltin oxide to form the stannylidene acetal, which was subjected to 4-phenoxybenzyl bromide and acetic anhydride. Finally, lactosamine 101 was easily prepared under glycosylation conditions involving acceptor 97 and donor 100, followed by removal of the acetate protecting groups. Interestingly, compound 101 was more selective for galectin-3 ( were also accomplished (69). X-ray crystallography revealed cation-π interactions between lactosamine aryl substitutions and arginine residues from the CRD. This research was the foundation for the development of a sensitive microarray for the ranking of galectin inhibitors (70) . Thus, glycan microarray based on evanescentfield fluorescence detection was used to screen novel lactosamine functionalized at C2 and C3′ positions by aromatic substituents.
C-3. Synthesis of Multivalent Inhibitors
Multivalent carbohydrate-protein interactions mediate a large number of important physiological processes (71) . Hence, the synthesis of multivalent glycoconjugates could be used to study, rationalize, and understand carbohydrate-galectin interactions (72) .
The proto type and tandem repeat type galectins are both divalent cross-linkers, as opposed to galectin-3, which is better known for its ability to act as efficient multivalent cross-linkers (73, 74) . Over the years, various types of multivalent platforms were exploited for galectin inhibition, i.e., dimers, small clusters, glycodendrimers and even self-assembled multivalent pseudopolyrotaxanes (75) . This section will describe efforts on the preparation of multivalent glycoconjugates as galectin inhibitors. These studies often led to very potent candidates benefiting from a synergic and cooperative effect known as the "glycoside or dendritic effect." In fact, it is well established that multivalency could offer numerous benefits in terms of affinity and receptor selectivity versus weaker monovalent interaction (71) .
As early as 1999, multivalent lactosides were developed to probe multivalent ligand functions in galectins (76) . Later, the group of Gabius presented simple divalent and trivalent galactosides and lactosides (77) . The best inhibitor against galectin-1 is presented in Scheme 28 and followed a route previously described The group of Roy also described the preparation and inhibitory properties of simple homo-and hetero-lactoside and galactoside dimers (37) . Out of the four triazole dimers prepared, compound 127 was active against galectins-1 and -3 (inhibitory properties of 0.3 mM and 0.16 mM, respectively) (Scheme 34c). charide structural moieties and the simplicity of the synthetic approach.
The flexibility in varying ring size, molecular shape, conformational flexibility, symmetry, and valency makes calix[n]-arenes unique tools to study glycocluster-protein interactions.
The group of Gabius and Ungaro synthesized calix[n] arene-based glycoclusters for their potential selectivity and avidity against galectins and the synthetic route is described in Scheme 35a (90) .
Thus, the p-tert-butyl calixarene precursor 134 was first converted into the corresponding nitro calixarene 135 using NaNO 3 and CF 3 CO 2 H. Reduction of the nitro groups using hydrazine hydrate in the presence of Pd/C led to the corresponding polyamine 136, which reacted with β-galactosyl or β-lactosyl isothiocyanates.
After deprotection of acetyl groups using Zemplèn conditons, the general procedure generated 14 calix[n] arene-based glycoclusters ("calixsugars") that were isolated and evaluated against Viscum album agglutinin and galectins-1, -3 and -4 using solid-phase inhibition assays. Inhibitory potencies showed that 6Lac [6] 
D. Conclusion and Outlook
Considering the role of these galectins in cancer-related processes it is clear that the quest for optimized galectin ligands represents a major challenge that is necessary for public health.
Thus, the long-standing synthetic efforts carried out by numerous research groups is an important endeavour. The present review emphasizes the synthetic strategies used to prepare galectin inhibitors that could have a highly promising future as drug targets. Ideally, high-avidity ligands combining specificity, selectivity, and synthetic accessibility with simple carbohydrate-based structures could rapidly emerge as efficient lead candidates. Because glycochemists already possess powerful synthetic and biological assets, the hope of seeing the development of optimized galectin inhibitors in clinical trials in the next decade is a likely reality. We are convinced that the clever combination of both intrinsic ligand fine-tuning and multivalency strategies could lead to potent candidates ready to enter clinical trials.
